Augmedix, Inc. (NASDAQ:AUGX – Get Free Report) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totalling 1,320,000 shares, a decline of 15.9% from the August 15th total of 1,570,000 shares. Approximately 2.7% of the shares of the stock are short sold. Based on an average trading volume of 862,500 shares, the days-to-cover ratio is presently 1.5 days.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the company. B. Riley downgraded Augmedix from a “strong-buy” rating to a “hold” rating and cut their price objective for the stock from $3.00 to $2.35 in a report on Friday, July 19th. William Blair lowered Augmedix from a “strong-buy” rating to a “hold” rating in a report on Friday, July 19th. Finally, Lake Street Capital restated a “hold” rating on shares of Augmedix in a research note on Monday, July 22nd. Four investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $3.09.
Get Our Latest Research Report on AUGX
Institutional Investors Weigh In On Augmedix
Augmedix Price Performance
Shares of NASDAQ AUGX remained flat at $2.33 during midday trading on Wednesday. The stock had a trading volume of 24,056 shares, compared to its average volume of 663,931. The company has a market capitalization of $114.10 million, a price-to-earnings ratio of -5.42 and a beta of -0.22. The business has a 50 day moving average of $2.09 and a 200 day moving average of $2.25. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 1.48. Augmedix has a one year low of $0.73 and a one year high of $6.25.
Augmedix (NASDAQ:AUGX – Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The business had revenue of $13.66 million for the quarter, compared to analyst estimates of $13.68 million. Augmedix had a negative return on equity of 182.36% and a negative net margin of 46.23%. On average, equities research analysts anticipate that Augmedix will post -0.45 EPS for the current year.
Augmedix Company Profile
Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.
See Also
- Five stocks we like better than Augmedix
- What is a Secondary Public Offering? What Investors Need to Know
- This Is the Top Large-Cap Stock Insiders Are Buying
- Which Wall Street Analysts are the Most Accurate?
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Stocks to Take Advantage of Rising Gold Prices
Receive News & Ratings for Augmedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Augmedix and related companies with MarketBeat.com's FREE daily email newsletter.